ISTA Pharmaceuticals
![]() | |
Type | Subsidiary |
---|---|
Industry | Pharmaceuticals |
Founded | 1992 |
Headquarters | Irvine, California |
Key people | Vicente Anido Jr., Ph.D. (President, Chief Executive Officer) Glenn E. Davis (Vice President, Chief Compliance Officer) Marvin J. Garrett (Vice President, Regulatory Affairs, Quality & Compliance) Kathleen McGinley (Vice President, Human Resources & Corporate Services) |
Products | Bromday, Bepreve, Xibrom, Istalol, Vitrase |
Website | www |
ISTA Pharmaceuticals, Inc, was a US-based pharmaceutical company that specialized in ophthalmic pharmaceutical products and discovers, develops, and markets therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye.[1] ISTA was acquired by Bausch & Lomb, an eye care company, on March 26, 2012.[2] Under the deal, Bausch & Lomb have agreed to pay $9.10 per share for ISTA, bringing the total value of the acquisition to $500 million.[3]
In 2012, Valeant Pharmaceuticals withdrew its $360 million offer.[4]
Products[]
- Bromday (bromfenac ophthalmic solution) 0.09% for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction[5]
- Bepreve (bepotastine besilate ophthalmic solution) 1.5% for the treatment of itching associated with signs and symptoms of allergic conjunctivitis[6]
- Xibrom (bromfenac ophthalmic solution) 0.09% for the treatment of inflammation and pain following cataract surgery (no longer being manufactured as of February 2011)
- Istalol (timolol maleate ophthalmic solution) 0.5% for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma[7]
- Vitrase (hyaluronidase injection) Ovine, 200 USP units/mL for use as an adjuvant to increase the absorption and dispersion of other injected drugs; for hypodermoclysis; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents[8]
Litigation[]
On May 24, 2013, ISTA Pharmaceuticals entered a guilty plea to federal felony charge of conspiracy to introduce a misbranded drug into interstate commerce and conspiracy to pay illegal remuneration in violation of the Federal Anti-Kickback Statute. ISTA agreed to pay $33.5 million to resolve criminal and civil liability arising from its marketing, distribution and sale of its drug Xibrom.[9]
References[]
- ^ "ISTA: Profile for ISTA Pharmaceuticals, Inc. - Yahoo! Finance". Finance.yahoo.com. Retrieved October 28, 2009.
- ^ Lattman, Peter. "Bausch & Lomb to Buy ISTA Pharmaceuticals for $500 Million". DealBook. Retrieved January 29, 2019.
- ^ Lattman, Peter (2012-03-26). "Bausch & Lomb to Buy ISTA Pharmaceuticals for $500 Million". DealBook. Retrieved 2019-10-21.
- ^ Scott, Mark. "Valeant Sticks to Torrid Pace of Deal-Making". DealBook. Retrieved January 29, 2019.
- ^ "Archived copy". Archived from the original on 2011-07-13. Retrieved March 21, 2011.CS1 maint: archived copy as title (link)
- ^ "Relief from Allergic Conjunctivitis - BEPREVE : Bausch + Lomb". www.Bausch.com. Retrieved January 29, 2019.
- ^ "Bausch Consumer > en > ecp > our-products". www.Bausch.com. Retrieved January 29, 2019.
- ^ "Bausch Consumer > en > ecp > our-products". www.Bausch.com. Retrieved January 29, 2019.
- ^ "ISTA Pharmaceuticals Inc. Pleads Guilty to Federal Felony Charges; Will Pay $33.5 Million to Resolve Criminal Liability and False Claims Act Allegations". www.Justice.gov. May 24, 2013. Retrieved January 29, 2019.
External links[]
- Companies based in Irvine, California
- American companies established in 1992
- Pharmaceutical companies established in 1992
- Pharmaceutical companies of the United States
- Companies formerly listed on the Nasdaq
- Health care companies based in California
- United States manufacturing company stubs